MAPS Public Benefit Corporation

MAPS Public Benefit Corporation
Name	MAPS Public Benefit Corporation
Type	Public benefit corporation
Industry	Biotechnology
Founded	2011
Founder	Rick Doblin
Headquarters	Santa Cruz, California
Key people	Rick Doblin, MD (Founder),Kathleen Harrison,Matthew Johnson (psychologist)
Products	Clinical trials, psychedelic therapy protocols

MAPS Public Benefit Corporation is an American public benefit corporation that develops psychedelic-assisted therapies and conducts clinical research into psilocybin, MDMA, and other psychoactive substances. It operates as a for-profit affiliate of the nonprofit Multidisciplinary Association for Psychedelic Studies and engages with regulatory agencies, academic centers, and private partners to advance novel treatment models. The organization has been central to recent dialogues involving Food and Drug Administration, Drug Enforcement Administration, and international drug policy reform.

History

MAPS Public Benefit Corporation was established in 2011 as a distinct legal entity to undertake drug development activities separate from the nonprofit Multidisciplinary Association for Psychedelic Studies. Early initiatives built on MAPS' involvement in research dating to the 1980s and 1990s including collaborations with investigators at Johns Hopkins University, Imperial College London, NYU Langone Health, and UCSF. The corporation worked to navigate pathways established by the Food and Drug Administration's breakthrough therapy designation program and engaged with precedent-setting trials such as phase II and phase III studies for MDMA-assisted psychotherapy in complex post-traumatic stress disorder contexts. Major milestones include submissions to the Food and Drug Administration and coordination with the Drug Enforcement Administration over scheduling and access frameworks.

Mission and Structure

The stated mission centers on developing FDA- and European Medicines Agency-compliant therapies derived from controlled substances, scaling protocols for clinical use, and ensuring social benefit aligned with public health objectives articulated by organizations like the World Health Organization and United Nations Office on Drugs and Crime. As a public benefit corporation, its governance model draws on corporate forms used by entities such as Patagonia (company) and Ben & Jerry's to balance fiduciary duties and public-interest goals. Leadership has involved figures with ties to academic institutions, regulatory affairs experts, and clinical investigators who have published in journals like The New England Journal of Medicine and JAMA Psychiatry.

Research and Clinical Programs

Research programs have targeted indications such as post-traumatic stress disorder studied using MDMA, and treatment-resistant depression investigated with psilocybin. Clinical trials were conducted at sites including Massachusetts General Hospital, Mount Sinai Health System, Yale School of Medicine, and international centers like Karolinska Institutet and University College London. Protocol development referenced psychotherapy models employed in trials at Johns Hopkins University, and outcome measures aligned with instruments used in multicenter studies sponsored by agencies such as the National Institutes of Health and foundations like Bezos Earth Fund (as philanthropic exemplars). The corporation developed training curricula for therapists modeled on frameworks used in cognitive behavioral therapy-based trials, and collaborated with contract research organizations similar to ICON plc and PPD, Inc. for trial management.

Regulatory Approvals and Legal Status

MAPS Public Benefit Corporation engaged with regulatory processes including Investigational New Drug applications to the Food and Drug Administration, and scheduling discussions with the Drug Enforcement Administration and international bodies following precedents set in policy debates involving Portugal drug policy reform and initiatives in Oregon Ballot Measure 110. The company's programs navigated orphan designation pathways and breakthrough therapy designations comparable to those granted by the European Medicines Agency for other novel biologics. Legal counsel and compliance teams referenced case law and statutes under the Controlled Substances Act while coordinating with state health departments in jurisdictions experimenting with regulatory models, including Colorado Amendment 64 and municipal reforms in Denver.

Funding and Partnerships

Funding sources included philanthropic donors, strategic partnerships with biotechnology firms, and revenue-generating agreements with training and commercialization partners. The organization received philanthropic support consistent with major donors to biomedical research such as foundations akin to Leonard A. Lauder Foundation or family offices similar to those that back medical initiatives. Partnerships were forged with academic medical centers, contract manufacturers resembling Catalent and laboratory service providers like Covance to ensure Good Manufacturing Practice standards. Collaborations also involved patient advocacy groups akin to Veterans of Foreign Wars and mental health organizations similar to National Alliance on Mental Illness for recruitment and dissemination.

Controversies and Criticism

Criticism has arisen around conflicts of interest between nonprofit research sponsors and for-profit commercialization entities, echoing debates seen in cases involving university spin-offs and biotech startups tied to universities such as Stanford University and MIT. Ethical concerns were raised about participant safety, informed consent, and therapist training standards, paralleling scrutiny in discussions about psychedelic research at institutions like Johns Hopkins University and Imperial College London. Critics pointed to commercialization risks comparable to controversies in pharmaceutical industry histories involving companies like Purdue Pharma and questioned equitable access discussed in policy forums alongside World Health Organization equity initiatives. Regulatory debates invoked comparisons to legal disputes over drug scheduling heard in federal courts and before administrative bodies such as the United States Court of Appeals for the D.C. Circuit.

Impact and Reception

The corporation's work influenced clinical research agendas at major centers including Harvard Medical School and University of California, Los Angeles, shaped media narratives in outlets that cover biomedical innovation, and contributed to policy discussions at forums like the National Academies of Sciences, Engineering, and Medicine. Reception among clinicians and researchers ranged from enthusiastic adoption by some investigators at institutions like Yale School of Medicine to cautious skepticism from ethicists at universities such as Princeton University and public health scholars at Columbia University Mailman School of Public Health. Its trials and advocacy played a role in shifting regulatory and public perceptions of psychedelic therapies, informing subsequent initiatives in pharmaceutical development and mental health services.

Category:Psychedelic research organizations